The NSD3 (Nuclear Receptor Binding SET Domain Protein 3) antibody is a critical tool for studying the role of NSD3. a histone methyltransferase involved in epigenetic regulation. NSD3. part of the NSD family, catalyzes the dimethylation of histone H3 at lysine 36 (H3K36me2), influencing chromatin structure and gene expression. It has garnered attention due to its oncogenic potential, particularly through gene amplifications or fusions (e.g., NSD3-NUTM1) observed in cancers like breast cancer, lung squamous cell carcinoma, and leukemia. Dysregulated NSD3 activity is linked to aberrant cell proliferation, differentiation, and therapy resistance, such as in tyrosine kinase inhibitor-resistant cancers.
NSD3 antibodies are widely used in research to detect protein expression, localization, and interactions via techniques like Western blotting, immunohistochemistry, and immunoprecipitation. They help elucidate NSD3's role in disease mechanisms, including its interplay with oncogenic pathways (e.g., MYC) and its potential as a therapeutic target. Commercially available antibodies vary in specificity, targeting distinct epitopes (e.g., N-terminal, catalytic SET domain). Validation using knockout cell lines or siRNA is essential to ensure reliability. Recent studies also explore NSD3 inhibitors, underscoring the antibody's utility in preclinical drug development. Overall, NSD3 antibodies are vital for advancing our understanding of epigenetic dysregulation in cancer and other diseases.